Corifollitropin Alfa
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Corifollitropin Alfa: From Controlled Ovarian Stimulation to Gastroduodenitis
One-Sentence Summary
Corifollitropin alfa is a long-acting recombinant FSH (follicle-stimulating hormone) agonist originally approved for controlled ovarian stimulation (COS) in women undergoing assisted reproductive technology (ART). The TxGNN model predicts it may be effective for Gastroduodenitis, with a prediction score of 99.65%. However, this prediction is supported by no clinical trials and no publications, making it a purely model-driven hypothesis at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Controlled ovarian stimulation (COS) for assisted reproductive technology (ART) |
| Predicted New Indication | Gastroduodenitis |
| TxGNN Prediction Score | 99.65% |
| Evidence Level | L5 |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on known pharmacology, Corifollitropin alfa is a long-acting recombinant fusion protein combining FSH with the carboxy-terminal peptide (CTP) of human chorionic gonadotropin (hCG). It acts as an FSH receptor (FSHR) agonist, stimulating follicular growth and development in the ovaries. A single subcutaneous injection sustains follicular stimulation for approximately one week, replacing the first seven daily FSH injections in a COS cycle.
The predicted link to gastroduodenitis rests on a highly speculative biological hypothesis: FSHR has been detected at low levels in non-reproductive tissues, including some gastrointestinal epithelial cells, and FSH signalling may indirectly modulate local inflammatory responses through the NF-κB pathway. If this expression were functionally relevant, an FSH agonist could theoretically influence mucosal inflammation in the stomach and duodenum.
In practice, however, this mechanistic bridge is extremely tenuous. Gastroduodenitis is primarily driven by Helicobacter pylori infection, NSAIDs use, and acid-related mucosal injury — pathways with no established connection to FSH/FSHR biology. The TxGNN high score most likely reflects a non-specific artefact arising from how inflammation-related nodes cluster together in the underlying knowledge graph, rather than a genuine biological relationship. There are no preclinical, in vitro, or clinical data to support FSH agonism as a treatment strategy for gastroduodenitis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Denmark Market Information
Corifollitropin alfa (brand name: Elonva®) holds a centralised European Marketing Authorisation issued by the EMA, but is currently not marketed in Denmark. No national (Laegemiddelstyrelsen) or active centralised authorisations are recorded for Denmark in this Evidence Pack.
| Marketing Authorisation Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| — | — | — | No active authorisation in Denmark |
Note for healthcare professionals: Elonva® (EU/1/09/609) has EMA centralised approval for COS in women undergoing ART, but market availability in Denmark should be confirmed directly with the Danish Medicines Agency (Laegemiddelstyrelsen) or the marketing authorisation holder (MSD/Organon).
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication (gastroduodenitis) is supported exclusively by the TxGNN model score; there are zero clinical trials, zero published studies, and no established mechanistic pathway connecting FSH receptor agonism to gastroduodenal inflammation. Furthermore, Corifollitropin alfa is not marketed in Denmark, and complete safety data (SmPC warnings, contraindications) were unavailable for review. Proceeding under these circumstances would be premature.
To proceed, the following is needed:
- Mechanistic validation: Independent experimental evidence (in vitro or animal studies) demonstrating FSHR functional expression in gastric/duodenal mucosa and its role in inflammatory signalling
- Safety data retrieval: Full SmPC review (EMA product information for Elonva®) to assess warnings, contraindications, and known adverse events relevant to non-reproductive indications
- MOA documentation: Formal DrugBank/literature review to characterise the complete pharmacological profile of corifollitropin alfa beyond reproductive endocrinology
- Evidence generation: At minimum, a hypothesis-generating preclinical study before any clinical application could be considered
- Regulatory context: Clarification of Denmark market status and feasibility of off-label or investigational use given current EMA approval scope
⚠️ Research use only. This report is intended for drug repurposing research purposes and does not constitute medical advice. All repurposing candidates require clinical validation before any therapeutic application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.